Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125169002 | 12516900 | 2 | F | 20160703 | 20160630 | 20160712 | EXP | US-TEVA-670908USA | TEVA | WEISBERG LS. LACTIC ACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES MELLITUS. C-J-AM-SOC-NEPHROL 2015;10(8):1476-83. | 49.00 | YR | M | Y | 0.00000 | 20160712 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125169002 | 12516900 | 1 | PS | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Unknown | 1000MG; INCREASED TO 2500MG IN 3 DIVIDED DOSES | U | 75975 | |||||||||
| 125169002 | 12516900 | 2 | SS | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Unknown | 2500MG IN 3 DIVIDED DOSES | U | 75975 | |||||||||
| 125169002 | 12516900 | 3 | SS | FUROSEMIDE. | FUROSEMIDE | 1 | Unknown | 40MG DAILY; INCREASED TO 80MG TWICE DAILY | U | 0 | |||||||||
| 125169002 | 12516900 | 4 | SS | FUROSEMIDE. | FUROSEMIDE | 1 | Unknown | U | 0 | 80 | MG | BID | |||||||
| 125169002 | 12516900 | 5 | SS | FUROSEMIDE. | FUROSEMIDE | 1 | Intravenous (not otherwise specified) | 160MG | U | 0 | |||||||||
| 125169002 | 12516900 | 6 | SS | EPINEPHRINE. | EPINEPHRINE | 1 | Intravenous drip | U | 0 | ||||||||||
| 125169002 | 12516900 | 7 | SS | NOREPINEPHRINE | NOREPINEPHRINENOREPINEPHRINE BITARTRATE | 1 | Intravenous drip | U | 0 | ||||||||||
| 125169002 | 12516900 | 8 | C | METOPROLOL SUCCINATE. | METOPROLOL SUCCINATE | 1 | Unknown | U | 0 | ||||||||||
| 125169002 | 12516900 | 9 | C | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | Unknown | U | 0 | ||||||||||
| 125169002 | 12516900 | 10 | C | METOLAZONE. | METOLAZONE | 1 | Unknown | 2.5 MG DAILY; ADDED 1 MONTH EARLIER | U | 0 | |||||||||
| 125169002 | 12516900 | 11 | C | DOBUTAMINE | DOBUTAMINEDOBUTAMINE HYDROCHLORIDE | 1 | Intravenous drip | U | 0 | ||||||||||
| 125169002 | 12516900 | 12 | C | vancomycin | VANCOMYCIN | 1 | Intravenous drip | U | 0 | ||||||||||
| 125169002 | 12516900 | 13 | C | LEVOFLOXACIN. | LEVOFLOXACIN | 1 | Intravenous drip | U | 0 | ||||||||||
| 125169002 | 12516900 | 14 | C | METRONIDAZOLE. | METRONIDAZOLE | 1 | Intravenous drip | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125169002 | 12516900 | 1 | Type 2 diabetes mellitus |
| 125169002 | 12516900 | 2 | Type 2 diabetes mellitus |
| 125169002 | 12516900 | 3 | Congestive cardiomyopathy |
| 125169002 | 12516900 | 4 | Congestive cardiomyopathy |
| 125169002 | 12516900 | 5 | Congestive cardiomyopathy |
| 125169002 | 12516900 | 9 | Congestive cardiomyopathy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125169002 | 12516900 | OT |
| 125169002 | 12516900 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125169002 | 12516900 | Blood creatinine increased | |
| 125169002 | 12516900 | Contraindicated product administered | |
| 125169002 | 12516900 | Lactic acidosis | |
| 125169002 | 12516900 | Metabolic alkalosis | |
| 125169002 | 12516900 | Toxicity to various agents |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |